Pharmaceutical Technology
JULY 2, 2025
Robert Barrie July 2, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Yeztugo, injected twice a year, offers more convenient dosing than daily pills. The US Food and Drug Administration (FDA) approved Yeztugo last month , bringing a more convenient PrEP option for adults and adolescents at risk of HIV exposure.
IDStewardship
JUNE 19, 2025
AI-Generated Summary This article by infectious diseases pharmacist Aneeka Chavda outlines five key considerations for pharmacists in the treatment of Mycobacterium tuberculosis (TB), particularly drug-sensitive cases. The piece advocates for therapeutic drug monitoring (TDM) in specific high-risk groups to personalize treatment.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
JUNE 25, 2025
1,2 “There is an extraordinary unmet need in obesity treatment, which is the ability for patients to stop GLP-1 drugs without regaining weight. 1 “These early Revita data are better than I expected and suggest the potential to prevent the weight regain we see in practice.
Pharmacy Times
JUNE 23, 2025
The presentation emphasized early intervention and personalized treatment plans in managing type 2 diabetes, shifting from "treating to failure" to "treating to target." He was joined by Laura, a patient who began tirzepatide treatment shortly after being diagnosed with T2D.
Pharmaceutical Technology
JUNE 11, 2025
Robert Barrie June 11, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Gilead said it is “committed to working with regulatory authorities to resolve the issues underlying the clinical hold” Credit: Melnikov Dmitriy via Shutterstock. Gilead is considered the leading big pharma in HIV treatments.
Pharmacy Times
JUNE 16, 2025
SHOW MORE This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025. Literature suggests a 3% difference in the rate of FN between CSF agents filgrastim (Neupogen; Amgen)/filgrastim biosimilars and pegfilgrastim (Neulasta; Amgen)/pegfilgrastim biosimilars.
Pharmacy Times
JUNE 10, 2025
3 Although meloxicam injection delivers a non-opioid alternative for pain control, it is not recommended as a first-line agent when rapid onset of analgesia is needed due to its delayed onset. June 10, 2025. Accessed June 10, 2025. 2 REFERENCES 1. PR Newswire. Meloxicam: Selective COX-2 inhibition in clinical practice.
Expert insights. Personalized for you.
52 
Let's personalize your content